Literature DB >> 16048968

Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation.

J Guinea1, T Peláez, L Alcalá, M J Ruiz-Serrano, E Bouza.   

Abstract

We analyzed the activities of six antifungal drugs (amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin, and micafungin) against 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples. We did not find differences among the susceptibilities by site of isolation.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16048968      PMCID： PMC1196260          DOI： 10.1128/AAC.49.8.3495-3497.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Antimicrobial susceptibility testing of six clinical isolates of Aspergillus.

Authors:  M Kitahara; V K Seth; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

2.  Acquired itraconazole resistance in Aspergillus fumigatus.

Authors:  E Dannaoui; E Borel; M F Monier; M A Piens; S Picot; F Persat
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

3.  In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

4.  Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999.

Authors:  P H Chandrasekar; J L Cutright; E K Manavathu
Journal:  Diagn Microbiol Infect Dis       Date:  2001-12       Impact factor: 2.803

5.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

6.  Trends in the postmortem epidemiology of invasive fungal infections at a university hospital.

Authors:  A H Groll; P M Shah; C Mentzel; M Schneider; G Just-Nuebling; K Huebner
Journal:  J Infect       Date:  1996-07       Impact factor: 6.072

7.  Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.

Authors:  Eric Dannaoui; Joseph Meletiadis; Anna-Maria Tortorano; Françoise Symoens; Nicole Nolard; Maria-Anna Viviani; Marie-Antoinette Piens; Bernadette Lebeau; Paul E Verweij; Renée Grillot
Journal:  J Med Microbiol       Date:  2004-02       Impact factor: 2.472

8.  Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.

Authors:  M B Kurtz; I B Heath; J Marrinan; S Dreikorn; J Onishi; C Douglas
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

9.  Comparison of caspofungin and amphotericin B for invasive candidiasis.

Authors:  Jorge Mora-Duarte; Robert Betts; Coleman Rotstein; Arnaldo Lopes Colombo; Luis Thompson-Moya; Juanita Smietana; Robert Lupinacci; Carole Sable; Nicholas Kartsonis; John Perfect
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

10.  In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.

Authors:  C Lass-Flörl; G Kofler; G Kropshofer; J Hermans; A Kreczy; M P Dierich; D Niederwieser
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790
View more
  14 in total

1.  Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus.

Authors:  Paul Bowyer; Juan Mosquera; Michael Anderson; Mike Birch; Michael Bromley; David W Denning
Journal:  FEMS Microbiol Lett       Date:  2012-05-21       Impact factor: 2.742

2.  Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.

Authors:  Jon A Olson; Jill P Adler-Moore; Julie Schwartz; Gerard M Jensen; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era.

Authors:  Jesús Guinea; Sandra Recio; Teresa Peláez; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

4.  Conserved regulators of mating are essential for Aspergillus fumigatus cleistothecium formation.

Authors:  Edyta Szewczyk; Sven Krappmann
Journal:  Eukaryot Cell       Date:  2010-03-26

Review 5.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

6.  Is azole resistance in Aspergillus fumigatus a problem in Spain?

Authors:  Pilar Escribano; Teresa Peláez; Patricia Muñoz; Emilio Bouza; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

Review 7.  Posaconazole : a review of its use in the prophylaxis of invasive fungal infections.

Authors:  James E Frampton; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Voriconazole : a review of its use in the management of invasive fungal infections.

Authors:  Lesley J Scott; Dene Simpson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  In vitro antifungal susceptibility of clinically relevant species belonging to Aspergillus section Flavi.

Authors:  Sarah S Gonçalves; Alberto M Stchigel; Josep Cano; Josep Guarro; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

10.  Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Araceli Monzon; Maria J Buitrago; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.